Four current, attributable analyst targets were reviewed. After the third-quarter 2026 report, three firms revised their targets in the same session: Barrington's Michael Petusky lowered his target to $10 (Outperform), TD Cowen cut to $9 (Hold), and Canaccord Genuity's Caitlin Roberts reiterated Buy while trimming to $11. Stifel's Thomas Stephan held a $13 target (Buy) from August, representing the high end of the range. Together these yield a low-to-high range of $9 to $13 and a simple average of $10.75, rounded to a central target of $11.
The spread between the cautious $9 (TD Cowen) and the more constructive $13 (Stifel) shows genuine disagreement about how quickly Orthofix Medical Inc. (OFIX) can improve profitability. The overall tone is tilted toward Buy or Outperform ratings, but the direction of revisions has been consistently downward, as analysts cite slower-than-expected revenue and a longer path to margin goals. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to others in the industry.
With a latest verified price near $6.67, moving to $11 implies upside of approximately 65%, a very large move by any standard. The stock trades near the bottom of a 52-week range of roughly $6.52 to $16.57 and carries a market capitalization around $270 million. The path toward $11 would likely require the company to demonstrate sustained revenue growth, progress on adjusted EBITDA, and a return of investor confidence after repeated guidance recalibrations.
Several factors could support a recovery. Orthofix's integration of SeaSpine, acquired in 2023, is largely complete, and management has signaled improved demand and reaffirmed targets for positive free cash flow and EBITDA margin expansion over the coming years. The 7D FLASH spine navigation platform is a longer-term growth catalyst analysts have highlighted. Activist investor Engine Capital has accumulated shares, and insider buying has been positive. A deep discount to medical-device peers on an EV/EBITDA basis gives a valuation-driven argument for upside if execution improves. From what I see, this setup is important because it highlights potential catalysts that could shift sentiment.
The principal obstacle is execution. Orthofix remains unprofitable, with a current-year EPS estimate near negative $1.18 and a P/E ratio that is not meaningful on trailing losses. The third-quarter report was characterized as disappointing on revenue and adjusted EBITDA, prompting broad target reductions. Slowing demand, competitive pressure in spine, macroeconomic uncertainty around hospital capital spending, and continued valuation compression could all keep the stock well below $11.
Orthofix is trading just above its 52-week low near $6.52, which now serves as the most important support level. A decisive break below that area would open fresh downside. On the upside, the $10 psychological level sits just below the central target, while the $13 high-end analyst target and the broader $16 to $17 zone, near former highs, represent the most durable resistance levels. The long-term trend remains firmly downward until the stock can reclaim and hold higher ranges.
Analyst price targets generally reflect a roughly 12-month research horizon, though the exact horizon varies by firm. Key items to monitor include upcoming quarterly earnings and guidance, analyst target revisions, adjusted EBITDA trajectory, free cash flow generation, new product launches and FDA clearances, and any further accumulation by activist or insider holders. Changes in hospital and surgical procedure volumes are also directly relevant to demand. I’m watching this closely as execution metrics unfold.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. In my view, traders can use these signals to discover opportunities, track existing positions, and spot changing trends more efficiently than manual screening allows. For those following OFIX, these tools can add a systematic layer to fundamental research and help refine timing decisions around key levels.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
OFIX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 71 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 83%.
The Moving Average Convergence Divergence Histogram (MACD) for OFIX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 42 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
OFIX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OFIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OFIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where OFIX advanced for three days, in 202 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
OFIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 111 of 149 cases where OFIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. OFIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.747) is normal, around the industry mean (4.142). P/E Ratio (-5.178) is within average values for comparable stocks, (3.291). OFIX's Projected Growth (PEG Ratio) (48.825) is slightly higher than the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.431) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OFIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of surgical products to the spine and orthopedic markets
Industry MedicalNursingServices